PMID- 38376315
OWN - NLM
STAT- MEDLINE
DCOM- 20240221
LR  - 20240327
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 19
IP  - 7
DP  - 2023 Oct 1
TI  - A novel EML4-NTRK3 fusion in lung adenocarcinoma with dramatic response to 
      entrectinib.
PG  - 2045-2047
LID - 10.4103/jcrt.jcrt_231_21 [doi]
AB  - In-frame fusions in NTRK genes, with intact kinase domain, have been reported to 
      occur at higher frequencies in rare tumors like infantile fibrosarcoma, 
      congenital mesoblastic nephroma, and secretory carcinoma, whereas they occur at 
      very low frequencies in common malignancies like NSCLC and colon cancers 
      (0.1%-1%). Despite the rare occurrence, these alterations have gained importance 
      owing to approval of drugs like entrectinib and larotrectinib targeting the 
      kinase domain of the gene. More than 50 fusion partners have been described, and 
      only in-frame fusions result in constitutive ligand-independent kinase activity 
      leading to oncogenesis. The commonly reported NTRK fusions in the lung include 
      SQSTM1-NTRK1, ETV6-NTRK3, and SQSTM1-NTRK3. Detection of these rests on the use 
      of conventional modalities like Immunohistochemistry (IHC) and fluorescence in 
      situ hybridization (FISH); however, accurate characterization requires direct 
      sequencing methods. We report an interesting case of an NTRK fusion-positive 
      NSCLC, exhibiting good response to entrectinib.
CI  - Copyright (c) 2023 Copyright: (c) 2023 Journal of Cancer Research and Therapeutics.
FAU - Batra, Ullas
AU  - Batra U
AD  - Department of Medical Oncology, Section of Molecular Diagnostics, Pathology, 
      Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
FAU - Nathany, Shrinidhi
AU  - Nathany S
AD  - Department of Medical Oncology, Section of Molecular Diagnostics, Pathology, 
      Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
FAU - Sharma, Mansi
AU  - Sharma M
AD  - Department of Medical Oncology, Section of Molecular Diagnostics, Pathology, 
      Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
FAU - Jain, Parveen
AU  - Jain P
AD  - Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research 
      Centre, Delhi, India.
FAU - Mehta, Anurag
AU  - Mehta A
AD  - Department of Medical Oncology, Section of Molecular Diagnostics, Pathology, 
      Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
FAU - Bansal, Abhishek
AU  - Bansal A
AD  - Department of Medical Oncology, Section of Molecular Diagnostics, Pathology, 
      Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20230426
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Benzamides)
RN  - L5ORF0AN1I (entrectinib)
RN  - 0 (Indazoles)
RN  - 0 (Sequestosome-1 Protein)
SB  - IM
MH  - Humans
MH  - *Adenocarcinoma of Lung/drug therapy/genetics
MH  - *Benzamides
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - In Situ Hybridization, Fluorescence
MH  - *Indazoles
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Sequestosome-1 Protein
EDAT- 2024/02/20 12:50
MHDA- 2024/02/21 11:22
CRDT- 2024/02/20 09:33
PHST- 2021/02/07 00:00 [received]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2024/02/21 11:22 [medline]
PHST- 2024/02/20 12:50 [pubmed]
PHST- 2024/02/20 09:33 [entrez]
AID - 01363817-202319070-00050 [pii]
AID - 10.4103/jcrt.jcrt_231_21 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2023 Oct 1;19(7):2045-2047. doi: 10.4103/jcrt.jcrt_231_21. 
      Epub 2023 Apr 26.